Approval summary for bortezomib for injection in the treatment of multiple myeloma. - Wikidata - awgldk - TriplyDB

Approval summary for bortezomib for injection in the treatment of multiple myeloma.

Approval summary for bortezomib for injection in the treatment of multiple myeloma.

http://www.wikidata.org/entity/Q44951957

about

Specific small molecule inhibitors of Skp2-mediated p27 degradation Non-secretory multiple myeloma: from biology to clinical management Sustained proliferation in cancer: Mechanisms and novel therapeutic targets Profound activity of the anti-cancer drug bortezomib against Echinococcus multilocularis metacestodes identifies the proteasome as a novel drug target for cestodes Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.Induction of Apoptosis in U937 Cells by Using a Combination of Bortezomib and Low-Intensity Ultrasound A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study Bortezomib: the evidence of its clinical impact in multiple myeloma.Regulatory role of proteasome in determination of platelet life span Nanodelivery in airway diseases: challenges and therapeutic applications.Synthesis and carbohydrate binding studies of fluorescent alpha-amidoboronic acids and the corresponding bisboronic acids.Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells.Discovery and development of the anticancer agent salinosporamide A (NPI-0052).Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myeloma Carbohydrate recognition by boronolectins, small molecules, and lectins.Generating a generation of proteasome inhibitors: from microbial fermentation to total synthesis of salinosporamide a (marizomib) and other salinosporamides Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics.Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells.Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future.Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors Regulating the 20S proteasome ubiquitin-independent degradation pathway.Protein processing and inflammatory signaling in Cystic Fibrosis: challenges and therapeutic strategies.Gold(III)-dithiocarbamato peptidomimetics in the forefront of the targeted anticancer therapy: preclinical studies against human breast neoplasia.Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatment Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death.Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs Targeted therapies for prostate cancer.Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice.Wnt pathway activation and ABCB1 expression account for attenuation of proteasome inhibitor-mediated apoptosis in multidrug-resistant cancer cells.Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).Analysis of ubiquitin E3 ligase activity using selective polyubiquitin binding proteins Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.Proteasome inhibition and allogeneic hematopoietic stem cell transplantation: a review Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma.Bortezomib enhances expression of effector molecules in anti-tumor CD8+ T lymphocytes by promoting Notch-nuclear factor-κB crosstalk.

P2860

Q24596988-A042F1CA-0F22-45B3-996B-12D6573BAD6B Q28074785-5529B866-A65A-460C-A7BD-692D2CD59F68 Q28396388-B21E6823-45AD-4D6E-B034-1CF6FCB28707 Q28542496-68C90503-36F9-4056-8C98-DE558D73AF5D Q29994527-D35884C7-80FF-41D0-A016-4EA6DDA23434 Q30248842-67CD0D62-B9C3-4176-8ACE-2781DC93008C Q30366081-ED953F00-AF0D-43BA-A060-C0506189D5BC Q33367833-300D8E0C-F8B6-47D7-83C5-CCA91C54CD3D Q33387006-0605468F-E7F5-400F-B7E9-8252C06288EA Q33398291-507947CE-2F41-42F2-8631-08A25AA8AD8E Q33400724-01A77BF3-9B8A-4E12-AB5D-07169497799D Q33405368-184FE113-F778-472E-AEC4-32082D68EE99 Q33483926-342598F2-3814-4D92-B7BC-3CB0655BE070 Q33529350-30E40C27-A04C-429B-A3D4-572B373909BC Q33584749-A60AF347-683D-40D2-827E-BA669B0D44FA Q33622960-275358C4-A63A-442F-9302-9D84703EF458 Q33648344-F58C26FD-B829-4B7B-92EE-832A844ABB0F Q33691290-11E42E23-399B-40EF-B31E-74153AB3B689 Q33836952-5253E5C6-6284-4808-8A3B-6413176ECD2D Q34142223-37AE81FA-BEFC-4178-BD50-AEEDD406DE53 Q34154200-9C12D342-44A1-40B5-B11C-6CDB1D1288B5 Q34195083-4D69A638-6F63-42AF-81EF-5AED20E90DFB Q34198852-B88375E2-A579-49E7-9281-03517E43253E Q34218976-473BB4F2-93CC-4CDD-85FA-B149A9C6E4E9 Q34318192-8ADD8B3E-A32F-4361-AE55-D25F6223C50E Q35043552-29AE5E5E-C0DD-4369-936D-F432FA0712FB Q35083349-28D1554A-7DD1-47DE-9FDA-F4B727CCECA6 Q35596882-11BFBC99-0212-46CB-99F5-F7FA1D34EE8C Q35663049-86D8F5BD-795F-495F-9196-8CD86EEDF7CC Q35933211-EB6F7E23-CD71-403E-A339-4CC57EFF1F17 Q36028423-696B6103-3376-48AF-9AB5-D7C9D87CE661 Q36150842-8297C7A2-97A9-4BBF-BBB4-1F3B68B2B0AD Q36204764-D0260774-A7D9-4CC2-8361-17708C1F87F3 Q36216250-01856122-0CB5-4AB8-8F86-70F28CD25B4E Q36251308-0360C883-D7E5-46F0-A648-28BAA4B13319 Q36301123-72F5F0FB-785A-4D37-8F23-A861D033FBAA Q36378038-8F72CB67-1382-488B-8B4B-904A8893B7AD Q36408216-5E69D385-9F56-4183-95A6-B2706421EDD4 Q36413767-EFF5197F-7D9A-4E98-AC56-092FC819A4C1 Q36544872-628A2492-DB92-4CCD-B618-A4140D256E91

P2860

Approval summary for bortezomib for injection in the treatment of multiple myeloma.

http://www.wikidata.org/entity/Q44951957

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Approval summary for bortezomib for injection in the treatment of multiple myeloma.

@en

Approval summary for bortezomib for injection in the treatment of multiple myeloma.

@nl

type

label

Approval summary for bortezomib for injection in the treatment of multiple myeloma.

@en

Approval summary for bortezomib for injection in the treatment of multiple myeloma.

@nl

prefLabel

Approval summary for bortezomib for injection in the treatment of multiple myeloma.

@en

Approval summary for bortezomib for injection in the treatment of multiple myeloma.

@nl

P1433

Q44951957-F6469AD2-E8FB-4E7E-A14C-A179558AE85A

P1476

Q44951957-34A5F74C-C2B8-4B40-A240-2FC48C670208

P2093

Q44951957-00725415-E8E9-420F-825A-C8C419B2404E

Q44951957-05E6DDB8-EE23-4727-8D14-8A73D070EF4C

Q44951957-1EAD28A4-1FF4-4D60-9BE2-8893196EDCCD

Q44951957-27A3C7A3-A1FB-4B75-8F58-AC042C68FAFD

Q44951957-30569997-A0A0-4A83-BD19-B27FEB61A4E2

Q44951957-43D25B9E-D81A-4BEA-AA7F-1E972DE09EA5

Q44951957-44B6F956-50B3-467A-9380-8BF6406370EC

Q44951957-55A64D5C-3533-4D51-9A39-8346D32951D4

Q44951957-5978C838-59EE-48BC-9E43-0210C4F7A7DA

Q44951957-60788AC1-E96E-420D-B287-E19E7A319993

P304

Q44951957-961C1408-3FB7-4F4E-AD70-FB0AEDCB7D3E

P31

Q44951957-4AE23502-0CAA-4CB9-8B49-92BD9076F714

P356

Q44951957-23841E45-79AC-4DE0-8AE5-7BFB9FEE4F58

P407

Q44951957-BB9B273F-D8B1-47FF-B19C-B2E50DE20787

P433

Q44951957-E93FC763-A01C-4611-A802-568F8B34E84A

P478

Q44951957-85768112-9923-4411-815B-8A586478EA89

P577

Q44951957-F198B2EA-FA6E-4043-8736-A1139C09027B

P698

Q44951957-87436E52-7681-4E8B-B4AC-E14FFFC4B597

P356

1078-0432.CCR-03-0781

P1433

Clinical Cancer Research

P1476

Approval summary for bortezomib for injection in the treatment of multiple myeloma.

@en

P2093

Ann T Farrell

http://www.w3.org/2001/XMLSchema#string

Anwar Goheer

http://www.w3.org/2001/XMLSchema#string

Atiqur Rahman

http://www.w3.org/2001/XMLSchema#string

Cheng Yi Liang

http://www.w3.org/2001/XMLSchema#string

David E Morse

http://www.w3.org/2001/XMLSchema#string

Grant Williams

http://www.w3.org/2001/XMLSchema#string

Jogarao V Gobburu

http://www.w3.org/2001/XMLSchema#string

John Leighton

http://www.w3.org/2001/XMLSchema#string

Kimberly Benson

http://www.w3.org/2001/XMLSchema#string

Lilliam A Rosario

http://www.w3.org/2001/XMLSchema#string

P304

3954-3964

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-03-0781

http://www.w3.org/2001/XMLSchema#string

P407

P433

12 Pt 1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2004-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15217925

http://www.w3.org/2001/XMLSchema#string